Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/17/2017 07/18/2017 07/19/2017 07/20/2017 07/21/2017 Date
4.25(c) 4.25(c) 4.525(c) 4.7(c) 4.6(c) Last
0 1 000 360 000 325 000 49 000 Volume
0.00% 0.00% +6.47% +3.87% -2.13% Change
More quotes
Financials ( GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -0,10 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 46,00
Capi. / Sales2017 3,31x
Capi. / Sales2018 2,46x
Capitalization 13,6 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
06/30 PROTEOME SCIENCES : Stroke Diagnostic Presentation at EuroMedLab 2017 – Re..
06/15 THERMO FISHER SCIENTIFIC : Recognizes Tandem Mass Tag Grant Award Winners at ASM..
04/25 PROTEOME SCIENCES : AGM Statement and Result of AGM
04/25 PROTEOME SCIENCES : Trading Remains In Line With Expectations
04/03 PROTEOME SCIENCES : Appoints Richard Dennis Chief Commercial Officer
04/03 PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
03/31 PROTEOME SCIENCES : Annual Report and Accounts 2016
03/28 PROTEOME SCIENCES : Says "Much Yet To Do" As Loss Narrows In 2016
03/28 PROTEOME SCIENCES : Preliminary results for the year ended 31 December 2016 Noti..
03/23PROTEOME SCIENCES PLC : annual earnings release
More news
Sector news : Bio Therapeutic Drugs
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/30Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
06/30Proteome Sciences : Stroke Diagnostic Presentation at EuroMedLab 2017 &nd.. 
05/30Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
03/31Proteome Sciences : Annual Report and Accounts 2016  
03/28Proteome Sciences revenue rises in full year results  
More tweets
Qtime:6
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Technical analysis trends PROTEOME SCIENCES PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Non-Executive Chairman
Geoffrey John Ellis Chief Financial Officer, Secretary & Director
Ian H. Pike Executive Director & Chief Scientific Officer
William Dawson Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-16.36%18
AMGEN23.25%132 526
CELGENE CORPORATION19.00%107 551
GILEAD SCIENCES3.00%96 384
REGENERON PHARMACEUTICALS40.54%54 837
VERTEX PHARMACEUTICALS121.49%40 641